Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome

Group 1 - The article discusses Regenxbio (NASDAQ: RGNX) and its ongoing developments related to Wet AMD ABBV-RGX-314, with results expected to remain on track for 2026 [2] - The author operates the Biotech Analysis Central service, which provides in-depth analysis of various pharmaceutical companies and includes a library of over 600 biotech investing articles [2] - The service offers a model portfolio of more than 10 small and mid-cap stocks, along with live chat and analysis to assist healthcare investors in making informed decisions [2]